XSAU
4005
Market cap1.89bUSD
Nov 12, Last price
159.00SAR
Name
National Medical Care Company JSC
Chart & performance
P/E
22.35
P/S
4.44
EPS
7.12
Div yield, %
2.52%
Shrs. gr., 5y
-0.11%
Rev. gr., 5y
14.61%
Revenues
1.60b
+23.68%
Net income
318m
+6.65%
CFO
154m
-37.07%
Dividend
May 04, 20263 SAR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
National Medical Care Company is dedicated to the comprehensive establishment, ownership, operation, and maintenance of healthcare facilities across the Kingdom of Saudi Arabia. Its substantial portfolio includes the 325-bed Riyadh Care Hospital, the 459-bed National Hospital, the Family Health Care Center, and the Care Company for Pharmaceutical and Medical Distribution. In addition to these institutional services, the company also provides home healthcare. Founded in 2003, it is headquartered in Riyadh, Saudi Arabia.
Key people
Faraj bin Saad Al-Gabani
Non-Executive Vice Chairman of the Board · since 2025
Jahanzeb Ahmed Khan
Chief Financial Officer · since 2022
Muhammad Al-Fadhil Al-Shammar
Chief Executive Officer - Internal Audit · since 2022
Ibrahim Alkhelaif
Chief Operating Officer
Mohamed bin Abdulrahman Al-Q
Chief Human Resources Officer
Ibrahim Abdullah Al-Ammar
Chief Information Officer
Abdulaziz bin Saleh Alobaid
Chief Executive Officer, Managing Director, Executive Director · since 2022
Naseer Ali
Chief Strategy Officer
Badr bin Saqr Al-Otaibi
Chief Medical Executive
Saad bin Abdulmohsen Alfa
Non-Executive Director · since 2025
Bader bin Fahad Alathel
Non-Executive Director · since 2022
Ahmed bin Wazaa Alqahtani
Non-Executive Chairman of the Board · since 2025
Michael Davis
Non-Executive Director · since 2022
Bandar Sanad Aldahmashi
Independent Director · since 2025
Salman Abbas Al-rawaf
Independent Director · since 2025
Bashar bin Abdulaziz Abalkh
Independent Director · since 2022
Sami bin Suliman Alkhasha
Independent Director · since 2022
Mai bint Mohammed Al Hos
Independent Director · since 2022
Valuation
Title SAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||